Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market Report 2026

The human papillomavirus (hpv) cytomegalovirus (cmv) therapeutic market size has grown strongly in recent years. It will grow from $4.9 billion in 2025 to $5.31 billion in 2026 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to high global prevalence of hpv and cmv infections, rising incidence of virus-associated cancers, widespread adoption of prophylactic hpv vaccination programs, increasing burden of cmv infections in immunocompromised patients, advancements in antiviral drug development.

The human papillomavirus (hpv) cytomegalovirus (cmv) therapeutic market size is expected to see strong growth in the next few years. It will grow to $7.32 billion in 2030 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to growing demand for therapeutic vaccines, increasing focus on cancer immunotherapy, rising investments in antiviral r&d, expanding screening and early intervention programs, increasing awareness of congenital and chronic viral infections. Major trends in the forecast period include increasing development of therapeutic vaccines for hpv and cmv, growing adoption of immunotherapy-based antiviral treatments, rising focus on combination therapies for viral infection management, expansion of targeted treatments for virus-associated cancers, increasing clinical trials for next-generation antiviral drugs.

The increasing prevalence of cervical cancer is expected to drive the growth of the human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutic market in the coming years. Cervical cancer is a malignant tumor that develops in the cells of the cervix, the lower part of the uterus that connects to the vagina. The rise in cervical cancer cases is largely attributed to persistent infection with high-risk strains of HPV, which cause abnormal cervical cell changes that can progress to cancer if not detected and treated early. HPV and CMV therapeutics support cervical cancer management by targeting virus-driven disease progression and improving patient outcomes. These treatments reduce the risk of cancer development by providing antiviral therapies and immunotherapies, thereby enhancing long-term health and quality of life. For example, according to a report by the American Cancer Society in April 2024, approximately 20 million new cervical cancer cases were diagnosed globally in 2022, and this number is projected to increase to 35 million by 2050. Consequently, the rising prevalence of cervical cancer is fueling the growth of the HPV and CMV therapeutic market.

The growth of the HPV and CMV therapeutic market is also expected to be driven by rising healthcare expenditure. Healthcare expenditure encompasses total spending on medical services, treatments, and healthcare resources, funded by governments, insurers, and individuals to ensure accessible and quality care. Increased healthcare spending allows broader access to advanced antiviral treatments and preventive care, benefiting HPV and CMV therapeutics. For instance, in May 2024, the Office for National Statistics, a UK-based government department, reported that total healthcare expenditure increased by 5.6% in nominal terms from 2022 to 2023, a significant acceleration compared to the 0.9% growth observed in 2022. Therefore, growing healthcare expenditure is expected to propel the HPV and CMV therapeutic market forward.

Key companies in the HPV and CMV therapeutics market are focusing on developing innovative technologies, such as post-transplant anti-cytomegalovirus (CMV) treatments, to address unmet medical needs, enhance treatment efficacy, reduce resistance to existing therapies, and improve outcomes for immunocompromised patients. Post-transplant anti-CMV treatments are therapeutic interventions designed to prevent or manage CMV infections in organ or stem cell transplant recipients who are at high risk due to immunosuppression. For example, in June 2024, Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical firm, received approval from the Japanese Ministry of Health, Labour, and Welfare (MHLW) for LIVTENCITY (maribavir) to treat post-transplant CMV infection or disease resistant to current anti-CMV medications. This antiviral agent is the only treatment in Japan that specifically targets and inhibits the CMV-specific UL97 protein kinase, providing a novel mechanism of action distinct from traditional therapies.

Major companies operating in the human papillomavirus (hpv) cytomegalovirus (cmv) therapeutic market are Merck & Co. Inc., Pfizer Inc., GlaxoSmithKline plc, Moderna Inc., BioNTech SE, Gilead Sciences Inc., F. Hoffmann-La Roche AG, Sanofi S.A., AstraZeneca plc, Novartis AG, AbbVie Inc., Bristol Myers Squibb Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Vir Biotechnology Inc., Inovio Pharmaceuticals Inc., Dynavax Technologies Corporation, Hookipa Pharma Inc., Vaxart Inc., Bavarian Nordic A/S.

North America was the largest region in the human papillomavirus (HPV) cytomegalovirus (CMV) therapeutic market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human papillomavirus (hpv) cytomegalovirus (cmv) therapeutic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the human papillomavirus (hpv) cytomegalovirus (cmv) therapeutic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are affecting the HPV and CMV therapeutics market by increasing costs of imported active pharmaceutical ingredients, biologics manufacturing inputs, and specialized production equipment. These impacts are most significant for vaccine and immunotherapy segments and in regions such as North America and Europe that depend on global biopharmaceutical supply chains. While higher costs may influence pricing and accessibility, tariffs are also driving localization of vaccine production, regional sourcing of raw materials, and investments in domestic biomanufacturing capabilities, strengthening long-term supply security.

The human papillomavirus (hpv) cytomegalovirus (cmv) therapeutic market research report is one of a series of new reports that provides human papillomavirus (hpv) cytomegalovirus (cmv) therapeutic market statistics, including human papillomavirus (hpv) cytomegalovirus (cmv) therapeutic industry global market size, regional shares, competitors with a human papillomavirus (hpv) cytomegalovirus (cmv) therapeutic market share, detailed human papillomavirus (hpv) cytomegalovirus (cmv) therapeutic market segments, market trends and opportunities, and any further data you may need to thrive in the human papillomavirus (hpv) cytomegalovirus (cmv) therapeutic industry. This human papillomavirus (hpv) cytomegalovirus (cmv) therapeutic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics refer to medical treatments developed to manage, reduce, or eliminate infections caused by HPV and CMV. These therapeutics are designed to control viral replication, prevent disease progression, and relieve symptoms associated with conditions such as cervical cancer (HPV) and congenital infections or complications in immunocompromised individuals (CMV).

The primary types of HPV and CMV therapeutics include vaccines, antiviral drugs, and immunotherapies. Vaccines are biological formulations intended to stimulate immunity against specific infectious diseases. Administration routes include intramuscular, oral, and topical methods. The key indications cover cervical cancer, genital warts, head and neck cancer, and anal cancer. Distribution channels include hospitals, retail pharmacies, online pharmacies, and specialty clinics.

The human papillomavirus (HPV) cytomegalovirus (CMV) therapeutic market consists of revenues earned by entities providing specific services such as antiviral drug infusion and dispensing, therapeutic vaccine administration, genotypic resistance testing, viral load monitoring, patient counselling and follow-up care. The market value includes the value of related goods sold by the service provider or included within the service offering. The human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutic market also includes sales of antiviral medications, therapeutic vaccines targeting human papillomavirus strains, immunomodulators, monoclonal antibodies, and gene therapy-based treatments. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.